Tissue proteomics · biomarker discovery · targeted verification

From discovery proteomics to a candidate worth verifying.

An anonymous project demonstration showing how paired quantitative proteomics, biological context, and assay suitability were combined to reduce a broad discovery dataset to a targeted verification decision.

Explore candidate evidence See the decision logic

Paired tissuewithin-patient comparison

Label-freebroad discovery proteomics

Candidate panelevidence-based prioritization

SRM/MRMtargeted verification

Anonymousmodified display values

Analytical workflow

Discovery and verification answer different questions.

The discovery stage identifies plausible changes across many proteins. The verification stage tests whether selected candidates can be measured reproducibly and whether the direction of evidence persists in new samples.

01 / DESIGN

Preserve the pairing

Condition tissue was compared with its patient-matched adjacent tissue to reduce between-person variability.

02 / DISCOVER

Quantify broadly

Label-free proteomics measured a broad protein landscape and identified differential abundance patterns.

03 / PRIORITIZE

Build the shortlist

Effect consistency, statistical evidence, pathway context, and technical assay suitability were reviewed together.

04 / VERIFY

Measure selectively

A targeted SRM/MRM panel tested shortlisted candidates in an independent set of paired samples.

05 / DECIDE

Bound the claim

Verification supported candidate progression, but did not by itself establish clinical validity or diagnostic utility.

Broad proteomeQuantified discovery features

Differential setEffect and statistical screen

Context filterBiology and disease relevance

Assay-ready panelPeptide and measurement suitability

Priority candidatesIndependent targeted evidence

Interactive candidate explorer

Why did some candidates advance while others stopped?

Select an anonymous candidate to compare discovery consistency, targeted verification, and subgroup relevance. The displayed evidence scores and paired values are modified for this public demonstration.

Candidate 1

Extracellular matrix-associated signal

Priority for follow-up

DiscoveryConsistent increaseDirection retained across most paired samples.

Targeted verificationSupportedTargeted measurement retained the expected direction.

Subgroup relevanceEarly-stage enrichedThe strongest pattern appeared in an earlier disease subgroup.

Interpretation: Candidate 1 combined a stable discovery pattern with independent targeted support. It remained a candidate for further assay and cohort validation, not a clinically validated biomarker.

Paired discovery pattern

Modified representative values show why the matched design matters. Each line joins comparison and condition tissue from the same anonymous sample pair.

Illustrative subset only. Values, scale, and pair count do not reproduce the source study.

Verification decision

The targeted stage asks whether the candidate can be measured selectively and whether the expected biological direction survives in independent material.

Targeted assay signalDetected

Direction in new samplesConsistent

Stage associationSupported

Clinical validationStill required

Important distinction: targeted verification strengthens analytical and biological confidence. It does not establish sensitivity, specificity, clinical cutoff, prospective performance, or clinical utility.

What this demonstrates

A biomarker shortlist is an evidence decision.

Statistical significance was one input. Candidates also had to show paired consistency, biological plausibility, measurable surrogate peptides, independent targeted support, and a claim that stayed within the available evidence.

Use the matched design

Analyze within-patient changes rather than treating paired tissue as unrelated groups.

Do not rank by p-value alone

Review effect direction, consistency, pathway context, missingness, and assay feasibility.

Separate discovery from verification

Use independent targeted measurements to challenge, not merely repeat, the discovery result.

Define the next evidence gap

Progress the strongest candidates into larger cohorts, analytical validation, and intended-use studies.

Demonstration scope

Scientific logic preserved. Study identity removed.

This page is a public-facing analytical demonstration derived from a peer-reviewed quantitative proteomics workflow. It is not a reproduction of the publication or a clinical validation report.

What has been anonymized

Disease identity, institutions, investigators, authorship, cohort sizes, protein and peptide identities, exact values, statistical thresholds, instrument parameters, and dates are omitted or modified.

What remains scientifically representative

Paired condition and adjacent-comparison tissue design.
Broad label-free proteomics followed by candidate prioritization.
Targeted SRM/MRM verification in an independent sample set.
Assessment of subgroup relevance and limits on the biomarker claim.

What the example does not claim

The anonymous candidate labels do not map publicly to named proteins.
Displayed evidence scores are illustrative and are not clinical performance metrics.
Targeted verification does not establish clinical validity, diagnostic accuracy, or clinical utility.
No patient-level, client, employer, or unpublished information is disclosed.

All identifying and exact empirical details have been removed or modified for this website demonstration.